Acadian Asset Management closed out its stake in Geron Co. (NASDAQ:GERN) during the fourth quarter, according to its most recent disclosure with the SEC. The firm previously had a 3,813 share stake in the biopharmaceutical company, valued at approximately $12,201. Acadian Asset Management had fully closed out its position in biopharmaceutical company by the time it had filed its quarterly disclosure with the SEC.

Geron Co. (NASDAQ:GERN) opened at 3.20 on Monday. The stock has a 50 day moving average price of $4.26 and a 200-day moving average price of $3.79. Geron Co. has a 12 month low of $2.60 and a 12 month high of $5.30. The stock’s market cap is $506.31 million.

Geron (NASDAQ:GERN) last announced its quarterly earnings results on Thursday, November 5th. The biopharmaceutical company reported $0.17 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.12 by $0.05. The business had revenue of $35.40 million for the quarter, compared to analyst estimates of $17.87 million. The company’s revenue was up 22025.0% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.06) EPS. On average, analysts expect that Geron Co. will post ($0.03) EPS for the current year.

GERN has been the subject of several research analyst reports. Zacks Investment Research upgraded Geron from a “hold” rating to a “buy” rating and set a $5.75 price objective for the company in a research report on Tuesday, December 1st. FBR & Co. reiterated a “buy” rating on shares of Geron in a research report on Wednesday, December 30th. Piper Jaffray increased their price objective on Geron from $5.00 to $10.00 and gave the stock an “overweight” rating in a research report on Monday, December 7th. Janney Montgomery Scott initiated coverage on Geron in a research report on Thursday, December 17th. They issued a “buy” rating and a $6.50 price objective for the company. Finally, Oppenheimer reiterated a “buy” rating and issued a $5.50 price objective on shares of Geron in a research report on Monday, December 7th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Geron presently has an average rating of “Buy” and a consensus price target of $6.54.

Geron Corporation (NASDAQ:GERN) is a clinical stage biopharmaceutical company focused on the development of a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The Company operates in one segment, the discovery and development of therapeutic products for oncology. Telomerase is an enzyme that enables cancer cells, including malignant progenitor cells, to maintain telomere length, which provides a capacity for limitless, uncontrolled proliferation. Telomerase consists of two essential components: a ribonucleic acid (RNA) template (hTR), which binds to the telomere, and a catalytic subunit (hTERT) with reverse transcriptase activity, which adds a specific DNA (deoxyribonucleic acid) sequence to the chromosome ends. Using its nucleic acid chemistry, the Company designed imetelstat to be an oligonucleotide that targets and binds with high affinity to the active site of telomerase, thereby directly inhibiting telomerase activity and impeding malignant cell proliferation.

12 Month Chart for NASDAQ:GERN

Receive News & Ratings for Geron Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron Co. and related companies with MarketBeat.com's FREE daily email newsletter.